60 RUE DE WATTIGNIES, PARIS, I0
Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Issues Press Release Dated April 7, 2026
Provides Business Update and Reports Full Year 2025 Financial Results
Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
To Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
Statement Regarding Recent Media Speculation
Voting Rights and Shares Capital
To Participate in Investor Conferences in March
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence
Submission Upload
Free Writing Prospectus